Tools
Stock profile

Coya Therapeutics, Inc. (COYA)

COYA · Latest close $3.09 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$3.09
As of Nov 18, 2026
Tracked funds holding
1 of 149
2026 Q2 13F filings
Opened / added
0 / 0
vs previous quarter
Trimmed / exited
0
vs previous quarter

Coya Therapeutics, Inc. (COYA) is held by 1 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings. Latest close $3.09 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: none in the last 90 days · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Fundamentals
Revenue · FY2025
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Greenlight Capital — 1 tracked fund hold COYA. See all holders.

Insider and Congress activity

No insider open-market activity or Congress trades reported for this stock in the recent window. Insider trading · Politician trading.

Often held alongside

Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Greenlight Capital0.35%2,335,540HELD Q3 filed Nov 16

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: -46.6% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

7.402.632024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding54 of 8,857 filers
Long-only filers among them53
Change vs 2026 Q1no net change · 53 entered · 53 exited
Shares reported, all filers7,765,583
Reported value, all filers$45.7M

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryPharmaceutical Preparations (SIC 2834)
Revenue · FY2025$7.9M
Net income · FY2025$-21.2M
Total assets · FY2025$50.0M
Shares outstanding23,457,849
Market cap (at latest close)$72.5M

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Aug 7, 2026.

Short interest

Shares short · Oct 15, 20261,254,876
Share of shares outstanding5.35%
Days to cover8.61

Shares short at recent settlements — Jul 31, 2026: 1.1M · Aug 14, 2026: 1.1M · Aug 31, 2026: 1.1M · Sep 15, 2026: 1.2M · Sep 30, 2026: 1.2M · Oct 15, 2026: 1.3M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Aug 7, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 7K · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 4K · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Aug 7, 2026.

Insider trading · Form 4

Data unavailable — no Form 4 transactions for this ticker were parsed in the last 90 days.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Jul 27, 2026Orin HirschmanSC 13G/A764,6793.3%Jun 30, 2026SEC filing
Mar 12, 2026Dr. Reddy's Laboratories, Inc.SC 13G2,272,7279.7%Jan 30, 2026SEC filing
Jan 30, 2026The Vanguard GroupSC 13G/A899,1404.3%Dec 31, 2025SEC filing
Jan 28, 2026Orin HirschmanSC 13G/A1,108,1715.3%Dec 31, 2025SEC filing
Feb 14, 2025DME Capital Management, LPSC 13G/A1,267,6697.6%Dec 31, 2024SEC filing
Feb 10, 2025Orin HirschmanSC 13G/A1,333,9198.0%Dec 31, 2024SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 3 Lobbying Disclosure Act filings named this company as client, 2022–2022; most common issues: Budget/Appropriations (3), Medical/Disease Research/Clinical Labs (3).

Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

This stock does not currently pass any tracked screen.

Signal record

· Insider BEST — appeared in 2 of the last 20 quarterly lists; latest 2024 Q4, ranked #24 of 50.

Also held by the tracked funds that hold COYA — ranked by lift, the co-holding pattern described in Methodology: Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) · ASTRAZENECA PLC (AZN) · ABBOTT LABORATORIES (ABT) · NOVARTIS AG (NVS).

8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.

Recent 8-K filings

FiledItemsSource
Nov 10, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Oct 14, 20268.01 Other EventsSEC filing
Oct 5, 20268.01 Other EventsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

Merck & Co., Inc. (MRK) · Track Record: how the signals scored · Practice timing on COYA

One email a week: the week’s new filings and research. Subscribe free

← COUR  ·  CP →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.